Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Equivalence of JL14002 vs Ranibizumab in wAMD
CTR20213179Phase 3Completed
- Sponsor
- Jieke Biopharmaceutical
- Start
- Dec 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of JL14002 in exudative macular degeneration, sponsored by Jieke Biopharmaceutical. Started Dec 2021; status: completed.
02
Drugs
JL14002
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20213179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213179.